Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Rheumatology International
Erschienen in:

01.01.2025 | Review

Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review

verfasst von: Lakshmi Kattamuri, Bhavesh Mohan Lal, Nikhil Vojjala, Mansi Jain, Kunal Sharma, Siddharth Jain, Samer Al Hadidi

Erschienen in: Rheumatology International | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of various hematological malignancies. Recently, CAR-T has been used in refractory auto-immune diseases with initial encouraging results. In this systematic review, we examined the safety and efficacy of CAR-T in patients with refractory auto-immune diseases. PubMed/Medline, EMBASE, Web of Science, and Scopus search revealed 1552 articles, of which 24 were included for the final analysis. 80 patients with autoimmune diseases received CAR-T cell therapy, of which 52 patients had systemic lupus erythematosus, 16 patients had systemic sclerosis, 7 patients had idiopathic inflammatory myopathies, 2 patient had anti-phospholipid antibody syndrome, 2 patients had rheumatoid arthritis, and 1 patient had Sjogren’s disease. 44 patients got CD-19 CAR-T and 36 patients got BCMA/CD-19 compound CAR-T. All the patients achieved an immunosuppression-free state at the last follow-up. Of the 47 patients with follow-up data, 79 patients developed cytokine release syndrome (CRS) and 4 patients developed neurotoxicity. None of the patients had fatal adverse events with CAR-T cell therapy. CAR-T appears to be safe and effective in patients with refractory autoimmune diseases. Future studies are crucial to further validate these findings, explore long-term outcomes, and refine the treatment protocols to enhance efficacy and safety.
Literatur
1.
Wang L, Wang FS, Gershwin ME (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369–395PubMedCrossRef
2.
Schett G, Mackensen A, Mougiakakos D (2023) CAR T-cell therapy in autoimmune diseases. Lancet 402(10416):2034–2044PubMedCrossRef
3.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581PubMedCrossRef
4.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222–233PubMedPubMedCentralCrossRef
5.
Treppo E, Binutti M, Agarinis R, De Vita S, Quartuccio L (2021) Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives. J Clin Med 10:17CrossRef
6.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324PubMedPubMedCentralCrossRef
7.
Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3(7):e489–e497PubMedCrossRef
8.
Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62(8):2458–2466PubMedCrossRef
9.
10.
Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O (2018) B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 11:1756286418761697PubMedPubMedCentralCrossRef
11.
Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56(9):3044–3056PubMedCrossRef
12.
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365PubMedCrossRef
13.
Al Hadidi S, Heslop HE, Brenner MK, Suzuki M (2024) Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies. Mol Ther
14.
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine. 2011;3(95):95ra73–95ra73.
15.
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733PubMedPubMedCentralCrossRef
16.
Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82(8):1117–1120PubMedCrossRef
17.
Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D et al (2023) CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154–2162PubMedPubMedCentralCrossRef
18.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567–569PubMedCrossRef
19.
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S et al (2023) CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401(10379):815–818PubMedCrossRef
20.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S et al (2024) CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N Engl J Med 390(8):687–700PubMedCrossRef
21.
Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M et al (2019) Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 11:482CrossRef
22.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71PubMedPubMedCentralCrossRef
23.
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417PubMedCrossRef
24.
Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed
25.
van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:1
26.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15–29PubMedCrossRef
27.
Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76(5):792–801PubMedCrossRef
28.
Ross L, Stevens W, Wilson M, Huq M, Strickland G, Walker J et al (2020) Performance of the 2017 EUSTAR activity index in an scleroderma cohort. Clin Rheumatol 39(12):3701–3705PubMedCrossRef
29.
Steen VD, Medsger TA Jr (2001) Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 44(12):2828–2835PubMedCrossRef
30.
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127–2133PubMed
31.
Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q et al (2021) Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR. Stem Cell Rev Rep 17(6):2120–2123PubMedPubMedCentralCrossRef
32.
Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D et al (2024) Anti–CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med 391(4):376–378PubMedCrossRef
33.
Yuan Y, He S, Zhang W, Zhang H, Destefano V, Wada M et al (2023) POS1134 novel approach to treat systemic lupus erythematosus, by targeting the “root cause”, B cells and plasma cells, using BCMA-CD19 compound car. Ann Rheum Dis 82(Suppl 1):895CrossRef
34.
Feng J, Hu Y, Chang AH, Huang H (2023) CD19/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus: safety and preliminary efficacy data from a phase I clinical study. Blood 142:4835CrossRef
35.
Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M et al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83(10):1304–1314PubMedCrossRef
36.
Schett G, Bohr D, Mueller F, Hagen M, Bergmann C, Tur C et al (2024) POS0030 safety and preliminary efficacy of CD19 CAR-T cell treatment in rheumatic disease- data from the first part of the phase I/II castle basket study. Ann Rheum Dis 83(Suppl 1):327CrossRef
37.
Amber P, Richard F, Francis K, Justin C, Ranjita S, Ruthee B et al (2024) P95 First two US patients with lupus nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101. Lupus Sci Med 11:1
38.
Auth J, Müller F, Völkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol
39.
Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L et al (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187(18):4890–904.e9PubMedCrossRef
40.
Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Röhrich M, et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 2024; 83(4):543–6.
41.
Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Pappa V, Motte J et al (2024) Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis 83(11):1597–1598PubMedCrossRef
42.
Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M et al (2024) Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open 10(4):e004727PubMedPubMedCentralCrossRef
43.
Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z et al (2024) Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial. Mol Ther 32(11):3821–3828PubMedPubMedCentralCrossRef
44.
Schmelz JL, Navsaria L, Goswamy R, Chuang HH, Miranda RN, Lee HJ (2020) Chimeric antigen receptor T-cell therapy’s role in antiphospholipid syndrome: a case report. Br J Haematol 188(3):e5–e8PubMedCrossRef
45.
Friedberg E, Wohlfarth P, Schiefer AI, Skrabs C, Pickl WF, Worel N, et al. (2024) Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost
46.
Sheng L, Zhang Y, Song Q, Jiang X, Cao W, Li L et al (2023) Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Front Immunol 14:1298815PubMedPubMedCentralCrossRef
47.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930PubMedPubMedCentralCrossRef
48.
Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y et al (2021) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896–1903PubMedCrossRef
49.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 20(1):31–42PubMedCrossRef
50.
Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL et al (2021) Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 194(4):690–700PubMedPubMedCentralCrossRef
51.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G et al (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(1):91–103PubMedCrossRef
52.
Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO et al (2022) Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386(7):640–654PubMedCrossRef
53.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331–1342PubMedPubMedCentralCrossRef
54.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2023) Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 41(3):555–567PubMedCrossRef
55.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD et al (2021) KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398(10299):491–502PubMedPubMedCentralCrossRef
56.
Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C et al (2024) Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther 30(1):77CrossRef
57.
Wudhikarn K, Perales M-A (2022) Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant 57(10):1477–1488PubMedPubMedCentralCrossRef
58.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531–2544PubMedPubMedCentralCrossRef
59.
Illei GG, Yarboro CH, Kuroiwa T, Schlimgen R, Austin HA, Tisdale JF et al (2007) Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology (Oxford) 46(6):952–956PubMedCrossRef
60.
Adams EM, Pucino F, Yarboro C, Hicks JE, Thornton B, McGarvey C et al (1999) A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol 26(2):352–360PubMed
61.
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ et al (2024) Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 30(2):338–341PubMedPubMedCentralCrossRef
Metadaten
Titel
Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review
verfasst von
Lakshmi Kattamuri
Bhavesh Mohan Lal
Nikhil Vojjala
Mansi Jain
Kunal Sharma
Siddharth Jain
Samer Al Hadidi
Publikationsdatum
01.01.2025
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 1/2025
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-024-05772-5

Weitere Artikel der Ausgabe 1/2025

Isolated inflammatory involvement of the occipital artery in giant cell arteritis and polymyalgia rheumatica: findings from a retrospective analysis and the critical role of MRI in diagnosis

  • Open Access
  • Imaging

Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study

  • Observational Research

Higher serotonin levels among patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis compared to healthy controls assessed by liquid chromatography–tandem mass spectrometry (LC-MS)

  • Original Article

COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time

  • Correspondence

New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review

  • Case Based Review

Fatigue patterns surrounding biologic disease-modifying antirheumatic drug injection in patients with an inflammatory rheumatic disease: an ecological momentary assessment study

  • Open Access
  • Patient Opinion

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Dank Nasenspray seltener in die Notaufnahme

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise